Abstract
Different classes of drugs, discovered by serendipity, have been used successfully for migraine prevention for more than 40 years. The progressive knowledge of migraine pathophysiology, brain hyperexicitability, and the specific neurotransmitter systems involved in pain perception has driven the attempts at targeting two crucial mechanisms: the restoration of nociceptive dysmodulation and the inhibition of cortical hyperexcitability. The success of modern research trials with preventive migraine agents (mainly neuromodulators) and optimized treatment of acute attacks with drug combinations aimed at low serotonergic function, neurogenic inflammation, and central sensitization has translated into better outcomes for patients and physicians. Trials combining preventive migraine agents with nonpharmacologic behavioral headache management have yielded additional benefits over either approach alone. With the clinical application of this updated information from clinical trials, migraine impact on productivity, quality of life, and suffering will certainly be diminished. We hope that these achievements will create a stable path of management to benefit our patients, without interruption, into the foreseeable future.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References and Recommended Reading
Min-Suk Y, Savidou I, Diener HC, Limmroth V: Evidence-based medicine in migraine prevention. Expert Rev Neurother 2005, 5:333–341.
Ramadan N: Current trends in migraine prophylactics. Headache 2007, 47(Suppl 1):S52–S57.
Loder E, Biondi D: General principles of migraine management: the changing role of prevention. Headache 2005, 45(Suppl 1):S33–S47.
Cutrer M: Antiepileptic drugs: how they work in headache. Headache 2001, 41(Suppl 1):S3–S10.
Moskowitz MA, Bolay H, Dalkara T: Deciphering migraine mechanisms: clues from familial hemiplegic migraine genotypes. Ann Neurol 2004, 55:276–280.
Ferrari MD, Haan J: The genetics of headache. In Wolff’s Headache and Other Head Pain, edn 7. Edited by Siberstein SD, Lipton RB, Dalessio DJ. New York: Oxford University Press; 2001:73–84.
Greenberg DA: Calcium channel in neurological disease. Ann Neurol 1997, 42:275–282.
Knight YE, Bartsch T, Kaube H, Goadsby PJ: P/Q-type calcium channel blockade in the periaqueductal gray facilitates trigeminal nociception: a functional genetic link for migraine? J Neurosci 2002, 22:RC213.
Holroyd K, Martin PR, Nash JM: Psychological treatments of tension-type headaches. In The Headaches, edn 3. Edited by Olesen J, Goadsby PJ, Ramadan N, et al.: Philadelphia: Lippincott Williams & Wilkins; 2006:711–719.
Krymchantowski AV: Sumatriptan combined with naproxen sodium decreases migraine recurrence in clinical practice [abstract]. Arq Neuropsiquiatr 1995, 53(Suppl 3):47.
Krymchantowski AV, Adriano MV, Fernandes D: Tolfenamic acid decrease migraine recurrence when used with sumatriptan. Cephalalgia 1999, 19:186–187.
Krymchantowski AV: Naproxen sodium decreases migraine recurrence when administered with sumatriptan. Arq Neuropsiquiatr 2000, 58(Suppl 2-B):428–430.
Dodick DW: Triptan nonresponder studies: implications for clinical practice. Headache 2005, 45:156–162.
Smith TR, Sunshine A, Stark SR, et al.: Sumatriptan and naproxen sodium for the acute treatment of migraine. Headache 2005, 45:983–991.
Brandes J, Kudrow D, Stark SR, et al.: Sumatriptannaproxen for acute treatment of migraine: a randomized trial. JAMA 2007, 297:1443–1454.
Krymchantowski AV, Filho PM, Bigal ME: Rizatriptan vs. rizatriptan and trimebutine for the acute treatment of migraine: a double-blind, randomized, crossover, placebocontrolled study. Cephalalgia 2006, 26:871–874.
Tfelt-Hansen P, Olesen J: Increasing the effect of triptans in migraine. Lancet 2006, 368:1313–1314.
Evans RW, Pascual J, Láinez MJ, Leira R: Bending the rule of monotherapy for migraine prevention? Headache 2005, 45:748–750.
Krymchantowski AV: Combining therapies for the treatment of migraine. Is there a role? Expert Rev Neurother 2005, 5:145–147.
Krymchantowski AV, Bigal ME: Polytherapy in the preventive and acute treatment of migraine: fundamentals for changing the approach. Expert Rev Neurother 2006, 6:283–289.
Holroyd KA, Nash JM, Pingel JD, et al.: A comparison of pharmacological (amitriptyline HCL) and nonpharmacological (cognitive-behavioral) therapies for chronic tension headaches. J Consult Clin Psychol 1991, 59:387–393.
Holroyd KA, O’Donnell FJ, Stensland M, et al.: Management of chronic tension-type headache with tricyclic antidepressant medication, stress-management therapy, and their combination: a randomized controlled trial. JAMA 2001, 285:2208–2215.
Holroyd KA, Lipchick GL, Penzien DB: Behavioral management of recurrent headache disorders; empirical basis for clinical practice. In Best Practice: Developing and Promoting Empirically Supported Interventions. Edited by Dobson KS, Craig KD. Newbury Park, CA: Sage; 1988:193–212.
Silberstein SD, Saper JR, Freitag FG: Migraine: diagnosis and treatment. In Wolff’s Headache and Other Head Pain, edn 7. Edited by Silberstein SD, Lipton RB, Dalessio DJ. New York: Oxford University Press; 2001:121–246.
Pascual J, Leira R, Lainez JM: Combined therapy for migraine prevention? Clinical experience with a betablocker plus sodium valproate in 52 resistant migraine patients. Cephalalgia 2003, 23:961–962.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Krymchantowski, A.V., Jevoux, C.d.C. Migraine prevention trials and optimized acute therapy: Translating lessons learned into clinical practice. Current Science Inc 12, 220–223 (2008). https://doi.org/10.1007/s11916-008-0038-x
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11916-008-0038-x